{
    "nct_id": "NCT06101277",
    "official_title": "Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)",
    "inclusion_criteria": "1. Must have one of the following histologically and/or biochemically confirmed cancers:\n\n   1. Cohort A: Esophageal, Gastroesophageal Junction, Gastric\n   2. Cohort B: Small bowel\n   3. Cohort C: Colorectal and appendiceal\n   4. Cohort D: Biliary including gallbladder, intrahepatic and extrahepatic cholangiocarcinoma\n   5. Cohort E: Hepatocellular carcinoma\n   6. Cohort F: Pancreatic and ampullary\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. [Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",
    "miscellaneous_criteria": ""
}